

Debasish Sundi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/947748/publications.pdf>

Version: 2024-02-01

35
papers

1,149
citations

471509

17
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

1690
citing authors

#	ARTICLE	IF	CITATIONS
1	African American Men With Very Low-Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2991-2997.	1.6	220
2	Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. <i>Journal of Urology</i> , 2014, 191, 60-67.	0.4	127
3	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. <i>Nature Reviews Urology</i> , 2017, 14, 244-255.	3.8	108
4	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. <i>European Urology</i> , 2016, 70, 14-17.	1.9	79
5	Androgen conspires with the CD8 ⁺ T cell exhaustion program and contributes to sex bias in cancer. <i>Science Immunology</i> , 2022, 7, .	11.9	74
6	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 697-700.	1.9	65
7	Reclassification Rates Are Higher Among African American Men Than Caucasians on Active Surveillance. <i>Urology</i> , 2015, 85, 155-160.	1.0	64
8	Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience. <i>Prostate</i> , 2015, 75, 191-199.	2.3	49
9	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. <i>European Urology</i> , 2016, 69, 576-581.	1.9	42
10	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. <i>Cancer</i> , 2019, 125, 391-397.	4.1	37
11	Laparoscopic and Robotic Radical Prostatectomy Outcomes in Obese and Extremely Obese Men. <i>Urology</i> , 2013, 82, 600-605.	1.0	36
12	Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database. <i>Journal of Urology</i> , 2017, 197, 627-631.	0.4	35
13	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 448-458.	7.0	29
14	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. <i>European Urology</i> , 2020, 78, 387-399.	1.9	28
15	Identification of men with the highest risk of early disease recurrence after radical prostatectomy. <i>Prostate</i> , 2014, 74, 628-636.	2.3	24
16	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 496-504.	1.9	23
17	Surgical management of high-risk, localized prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 679-690.	3.8	20
18	A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder. <i>Urology Case Reports</i> , 2013, 1, 2-4.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. <i>Oncotarget</i> , 2017, 8, 34205-34222.	1.8	13
20	Invasive Fungal Bezoar Requiring Partial Cystectomy. <i>Urology</i> , 2012, 79, e21-e22.	1.0	11
21	Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. <i>Oncolmmunology</i> , 2019, 8, e1577125.	4.6	10
22	Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8â€“10) prostate cancer treated primarily by radical prostatectomy. <i>Cancer</i> , 2021, 127, 1425-1431.	4.1	10
23	Sex-biased adaptive immune regulation in cancer development and therapy. <i>IScience</i> , 2022, 25, 104717.	4.1	10
24	Limitations of Assessing Value in Robotic Surgery for Prostate Cancer: What Data Should Patients and Physicians Use to Make the Best Decision?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1394-1395.	1.6	5
25	Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e11-813.e19.	1.6	5
26	The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy. <i>Bladder Cancer</i> , 2019, 5, 103-114.	0.4	4
27	Optimizing the Management of High-Risk, Localized Prostate Cancer. <i>Korean Journal of Urology</i> , 2012, 53, 815.	1.2	3
28	Re: Steven Joniau, Alberto Briganti, Paolo Gontero, et al. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. <i>Eur Urol</i> 2015;67:157â€“64. <i>European Urology</i> , 2015, 68, e11-e12.	1.9	1
29	Progress in Prognosis and Prediction for Men with Prostate Cancer. <i>European Urology</i> , 2017, 72, 32-33.	1.9	1
30	Editorial Comment. <i>Urology</i> , 2014, 84, 1261-1262.	1.0	0
31	Brachytherapy for prostate cancer: feasible but oncological equivalence unproven. <i>BJU International</i> , 2015, 116, 89-91.	2.5	0
32	Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification.. <i>Journal of Clinical Oncology</i> , 2014, 32, 91-91.	1.6	0
33	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5036-5036.	1.6	0
34	Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. <i>Oncotarget</i> , 2019, 10, 1870-1871.	1.8	0
35	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 254-255.	0.4	0